Norman M. Kneteman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Norman M. Kneteman has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Abha R. Dunichand-Hoedl
Division of Human Nutrition, University of Alberta, Edmonton, Alberta, Canada
1 shared publication - Aldo J. Montano-Loza
Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada
1 shared publication - Alessandro Parente
Division of Transplantation, Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta Hospital, Edmonton T6G 2B7, Alberta, Canada
1 shared publication - Andrew Mark James Shapiro
Clinical Islet Transplant Program, University of Alberta, Edmonton, Canada
1 shared publication Blaire Anderson
Division of Transplantation, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada
1 shared publication- Christian Toso
Division of Digestive Surgery, University Hospitals of Geneva, Geneva, Switzerland
1 shared publication
Latest Publications
- Open Access
- 24 May 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (9) , 101455
Type II fibre atrophy and nuclear disruption in decompensated cirrhosis
- 24 May 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (9) , 101455
Open AccessType II fibre atrophy and nuclear disruption in decompensated cirrhosis
- Open Access
- 1 January 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (1) , 120-127
Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis
- 1 January 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (1) , 120-127
Open AccessTreatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis
- 8 July 2013
- Published by Wiley in Liver International
- Vol. 33 (9) , 1441-1448
Additive effect of sirolimus and anti‐death receptor 5 agonistic antibody against hepatocellular carcinoma
Background & Aims: Despite careful patient selection, hepatocellular carcinoma (HCC) recurs in 10–20% of cases after liver transplantation, and the use of potent adjuvant anticancer drugs would be welcome. The aim of this study was to evaluate the efficiency of a combined therapy of rapamycin (sirolimus) and anti‐death receptor (DR)5 monoclonal antibody (mAb) on HCC.Methods: We first assessed the side effects of anti‐DR5 mAb administration in vivo by giving various doses of anti‐DR5 mAb. Cell proliferation assays were then performed using mouse Hepa1‐6 cells or human Huh7 cells to quantify the relative cell viability under various concentrations of sirolimus, anti‐DR5 mAb or a combination. Next, one million Hepa1‐6 cells were transplanted into C.B17‐SCID‐beige mice subcutaneously, and four groups were created: (1) untreated, (2) anti‐DR5 mAb alone, (3) sirolimus alone and (4) anti‐DR5 mAb + sirolimus.Results: Anti‐DR5 mAb (200 and 300 μg/day) induced liver dysfunction with partial necrosis of the liver, but 100 μg/day was well tolerated with transaminitis, but normal bilirubin and only minor histological liver damage. In vitro, anti‐DR5 mAb lysed Hepa1‐6 and Huh7 cells in a dose‐dependent manner, and combinations of sirolimus and anti‐DR5 mAb demonstrated an additive effect. In vivo studies demonstrated that tumour sizes were significantly smaller in the combined therapy group than in the monotherapy groups.Conclusions: Combining sirolimus and low‐dose anti‐DR5 mAb has a significant effect against HCC. This strategy represents a potential novel approach for the management of HCC.
- 8 July 2013
- Published by Wiley in Liver International
- Vol. 33 (9) , 1441-1448
Additive effect of sirolimus and anti‐death receptor 5 agonistic antibody against hepatocellular carcinoma
Background & Aims: Despite careful patient selection, hepatocellular carcinoma (HCC) recurs in 10–20% of cases after liver transplantation, and the use of potent adjuvant anticancer drugs would be welcome. The aim of this study was to evaluate the efficiency of a combined therapy of rapamycin (sirolimus) and anti‐death receptor (DR)5 monoclonal antibody (mAb) on HCC.Methods: We first assessed the side effects of anti‐DR5 mAb administration in vivo by giving various doses of anti‐DR5 mAb. Cell proliferation assays were then performed using mouse Hepa1‐6 cells or human Huh7 cells to quantify the relative cell viability under various concentrations of sirolimus, anti‐DR5 mAb or a combination. Next, one million Hepa1‐6 cells were transplanted into C.B17‐SCID‐beige mice subcutaneously, and four groups were created: (1) untreated, (2) anti‐DR5 mAb alone, (3) sirolimus alone and (4) anti‐DR5 mAb + sirolimus.Results: Anti‐DR5 mAb (200 and 300 μg/day) induced liver dysfunction with partial necrosis of the liver, but 100 μg/day was well tolerated with transaminitis, but normal bilirubin and only minor histological liver damage. In vitro, anti‐DR5 mAb lysed Hepa1‐6 and Huh7 cells in a dose‐dependent manner, and combinations of sirolimus and anti‐DR5 mAb demonstrated an additive effect. In vivo studies demonstrated that tumour sizes were significantly smaller in the combined therapy group than in the monotherapy groups.Conclusions: Combining sirolimus and low‐dose anti‐DR5 mAb has a significant effect against HCC. This strategy represents a potential novel approach for the management of HCC.
- 1 February 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1831 (2) , 387-397
Characterization of lipid and lipoprotein metabolism in primary human hepatocytes
- 1 February 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1831 (2) , 387-397
Characterization of lipid and lipoprotein metabolism in primary human hepatocytes
- Open Access
- 1 February 1996
- Published by Wolters Kluwer Health in Transplantation
- Vol. 61 (4) , 630-634
TACROLIMUS (FK506)-ITS EFFECTS ON INTESTINAL GLUCOSE TRANSPORT1
Tacrolimus (FK506) is at present the mainstay of immunosuppression for small intestinal transplantation. This study investigates the effects of chronic treatment with varying dosages of tacrolimus on animal well-being, weight gain, intestinal permeability, and the active transport of nutrients as measured by in vitro studies quantifying glucose flux. The effect of acute treatment with high-dose tacrolimus on glucose flux was also investigated. In the chronic studies, juvenile male Lewis rats were given tacrolimus in a dosage of 0.1 mg/kg, 0.5 mg/kg, and 2 mg/kg q. second day by subcutaneous injection for five weeks. In the acute studies, animals were treated with 2 mg/kg given q. 24 hr [mult] 48 hr, 24 hr and 12 hr prior to sacrifice. In the acute treatment groups, tacrolimus caused no change in glucose flux. In the chronically treated animals, FK506 levels were within the clinically relevant range. Chronic treatment with 0.5 and 2 mg/kg caused a significant reduction in weight gain. These same groups of animals had a significant increase in intestinal permeability as measured by absorption of 99Te-DTPA. Glucose flux was affected in all chronically treated groups, with net flux increasing in the jejunum and decreasing in the ileum. These findings show that chronic treatment with low-dose tacrolimus is well tolerated, but in higher doses there are significant effects in intestinal permeability and nutrient uptake, and animal weight gain. We suggest that these changes are due to alterations in intestinal permeability that do not appear to be mediated by an acute drug effect and more likely represent chronic changes, possibly from alterations in gene expression. These findings suggest that further studies regarding the effects of tacrolimus on nutrient transport, intestinal permeability, and the known immunologically related functions of tacrolimus should be done.
- 1 February 1996
- Published by Wolters Kluwer Health in Transplantation
- Vol. 61 (4) , 630-634
Open AccessTACROLIMUS (FK506)-ITS EFFECTS ON INTESTINAL GLUCOSE TRANSPORT1
Tacrolimus (FK506) is at present the mainstay of immunosuppression for small intestinal transplantation. This study investigates the effects of chronic treatment with varying dosages of tacrolimus on animal well-being, weight gain, intestinal permeability, and the active transport of nutrients as measured by in vitro studies quantifying glucose flux. The effect of acute treatment with high-dose tacrolimus on glucose flux was also investigated. In the chronic studies, juvenile male Lewis rats were given tacrolimus in a dosage of 0.1 mg/kg, 0.5 mg/kg, and 2 mg/kg q. second day by subcutaneous injection for five weeks. In the acute studies, animals were treated with 2 mg/kg given q. 24 hr [mult] 48 hr, 24 hr and 12 hr prior to sacrifice. In the acute treatment groups, tacrolimus caused no change in glucose flux. In the chronically treated animals, FK506 levels were within the clinically relevant range. Chronic treatment with 0.5 and 2 mg/kg caused a significant reduction in weight gain. These same groups of animals had a significant increase in intestinal permeability as measured by absorption of 99Te-DTPA. Glucose flux was affected in all chronically treated groups, with net flux increasing in the jejunum and decreasing in the ileum. These findings show that chronic treatment with low-dose tacrolimus is well tolerated, but in higher doses there are significant effects in intestinal permeability and nutrient uptake, and animal weight gain. We suggest that these changes are due to alterations in intestinal permeability that do not appear to be mediated by an acute drug effect and more likely represent chronic changes, possibly from alterations in gene expression. These findings suggest that further studies regarding the effects of tacrolimus on nutrient transport, intestinal permeability, and the known immunologically related functions of tacrolimus should be done.